Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 + BCMA CAR-T
- Development stage
- Phase 1
- Lead developer
- Senlang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19 + BCMA CAR-T (SenlangBio) is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to simultaneously target CD19 and B-cell maturation antigen (BCMA). Developed by Hebei Senlang Biotechnology, this dual-targeted approach aims to deplete both B cells and long-lived plasma cells, which are key drivers in the pathogenesis of autoimmune diseases. The therapy is currently being evaluated in a Phase 1 clinical trial (NCT07435779) for the treatment of refractory and relapsing ulcerative colitis, where it is intended to induce clinical remission by resetting the immune system through the elimination of pathogenic B-cell lineages.
- Other names
- CD19/BCMA CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CD19 + BCMA CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 + BCMA CAR-T.